Researchers report they continue to be encouraged by ongoing analysis of a trial of Colostrinin as a treatment of Alzheimer's Disease.

The trial included 106 patients at six clinics in Poland, with the first phase consisting of a double-blind, placebo-controlled study. Patients received Colostrinin or a placebo for 15 weeks.

In the final phase, all remaining patients are receiving open-label Colostrinin for an additional 15-week period.

To this point, the data has reflected a slower rate of deterioration for patients treated with Colostrinin than those taking a placebo. Moreover, there are no current concerns for drug's safety, toxicity or side effects, the researchers report.

ReGen's team of scientists have hypothesized that the drug may work as an anti-oxidant, may prevent the formation of or dissolve Amyloid plaques and may alter the immune system. Although the majority of drugs currently on the market offer only symptomatic relief from the disease, makers of Colostrinin are hopeful that the drug will work to prevent -- and reverse -- the disease.

"We are extremely encouraged by these clinically interesting results," said ReGen's chief executive Mike Harvey. "If the safety and efficacy profile, shown in the first phase of this trial is maintained in its final phase, then Colostrinin has the potential to be one of the first therapies for Alzheimer's disease that will offer long term benefits."

Other sources: ReGen Therapeutics